Zurcher Kantonalbank Zurich Cantonalbank Increases Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 13.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,145 shares of the biotechnology company’s stock after acquiring an additional 5,155 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Iovance Biotherapeutics were worth $359,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Iovance Biotherapeutics by 116.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,356 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,414 shares during the last quarter. Annandale Capital LLC acquired a new position in Iovance Biotherapeutics in the third quarter valued at $32,000. Nisa Investment Advisors LLC grew its position in Iovance Biotherapeutics by 284.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 7,541 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 5,577 shares during the period. Clear Street Markets LLC acquired a new stake in Iovance Biotherapeutics during the third quarter worth about $35,000. Finally, AE Wealth Management LLC purchased a new position in shares of Iovance Biotherapeutics in the 3rd quarter worth about $48,000. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Merrill A. Mcpeak bought 250,000 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average price of $9.15 per share, for a total transaction of $2,287,500.00. Following the purchase, the director now owns 320,150 shares in the company, valued at approximately $2,929,372.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 10.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on IOVA shares. Piper Sandler boosted their target price on Iovance Biotherapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, March 14th. Chardan Capital lifted their target price on shares of Iovance Biotherapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday, February 20th. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 29th. JMP Securities raised their price objective on Iovance Biotherapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a research report on Tuesday, February 20th. Finally, StockNews.com raised Iovance Biotherapeutics to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $24.64.

Iovance Biotherapeutics Stock Up 5.8 %

Shares of NASDAQ IOVA opened at $13.63 on Friday. The business has a 50 day moving average price of $13.97 and a two-hundred day moving average price of $9.51. Iovance Biotherapeutics, Inc. has a fifty-two week low of $3.21 and a fifty-two week high of $18.33. The firm has a market cap of $3.81 billion, a PE ratio of -7.25 and a beta of 0.66.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.01). The firm had revenue of $0.48 million for the quarter, compared to analyst estimates of $1.44 million. During the same period in the prior year, the firm earned ($0.64) earnings per share. On average, analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.4 earnings per share for the current year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.